← Human Trials & Peer-Reviewed Studies
Abiraterone acetate plus LHRH therapy versus abiraterone acetate while sparing LHRH therapy in patients with progressive, metastatic and chemotherapy-naïve, castration-resistant prostate cancer (SPARE): study protocol for a randomized controlled trial.
Plain-language guide to PMID 28978327 (2017): randomized controlled trial of Gonadorelin.
Key Facts
- PMID
- 28978327
- Journal
- Trials
- Year
- 2017
- Study type
- Randomized Controlled Trial
- Authors
- Ohlmann CH et al. (7 authors)
- DOI
- 10.1186/s13063-017-2195-x
- Registered trial
- NCT02077634
What This Study Did, in Plain Language
What Was Tested
Researchers studied Gonadorelin in this randomized controlled trial publication.
The value of continuation of luteinizing hormone-releasing hormone (LHRH) therapy in castration-resistant prostate cancer (CRPC) remains controversial and clear evidence is lacking.
Argumentation for cessation of LHRH therapy is the prolonged suppression of testosterone levels after the withdrawal of LHRH analogues and the fact that disease progression occurs despite castration levels of testosterone.
Who Took Part
PubMed tags the participants as men only.
How the Study Was Run
The design is described as randomized.
Because people in this Gonadorelin study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.
What Was Measured
Argumentation for cessation of LHRH therapy is the prolonged suppression of testosterone levels after the withdrawal of LHRH analogues and the fact that disease progression occurs despite castration levels of testosterone.
Especially upon treatment with the life-prolonging cytochrome P450 17-alpha-hydroxylase (Cyp17)-inhibitor, abiraterone, which has the ability to further suppress testosterone serum levels over LHRH therapy alone, continuation of LHRH therapy seems to be negligible.
Topics PubMed links to this paper include Abiraterone Acetate, Antineoplastic Agents, Hormonal, Antineoplastic Combined Chemotherapy Protocols, Disease Progression, Disease-Free Survival, Germany and Gonadotropin-Releasing Hormone.
The authors tagged it with the keywords Castration-resistant prostate cancer, LHRH therapy, Luteinizing hormone and Testosterone.
What This Means in Plain Language
The paper is a randomized study of Gonadorelin.
Its findings take up roughly 2 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.
The publication is from 2017 (Trials), a journal based in England.
More context: the Gonadorelin compound page, all human trials.
Our Notes on the Compound
Gonadorelin: A synthetic version of gonadotropin-releasing hormone (GnRH), the signal that tells the pituitary to release LH and FSH.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.